Vorpal Technologies for Japan Market Entry

Local expertise for PMDA strategy, reimbursement, and DMAH support.

Through Vorpal Technologies K.K., our Tokyo-based team helps global medical device companies navigate PMDA requirements, regulatory strategy, reimbursement, and DMAH obligations.
CONTACT US
Sub Brands MedTech Homepage Regulatory Japan Medical Device Regulatory Consulting (DMAH & Shonin)

Streamline your path to market with our expert Japan medical device regulatory consultants

Japan offers significant opportunities for medical device manufacturers, but navigating PMDA requirements, reimbursement pathways, and local regulatory obligations can be complex. IQVIA MedTech's dedicated Japan regulatory team, built on the expertise and legacy of Vorpal Technologies K.K., helps manufacturers successfully navigate Japan medical device registration, PMDA submissions, Shonin approvals, reimbursement, and DMAH requirements.

Why manufacturers choose IQVIA MedTech and Vorpal Technologies K.K.:

  • Former PMDA reviewer and Tokyo-based specialists with deep expertise in Class III and IV medical devices.
  • A bilingual Japanese-English team that bridges communication between global manufacturers and Japanese regulators.
  • Independent DMAH services that preserve control of your registrations while maintaining distributor flexibility.
  • End-to-end support spanning regulatory strategy, PMDA submissions, QMS compliance, reimbursement, and post-market obligations.

Our Japan medical device regulatory consulting solutions

Regulatory & Clinical Evidence Generation

Regulatory & clinical support: From pre-market approval to lifecycle management

The Japanese medical device approval process is a structured, risk-based system requiring local Marketing Authorization Holders (MAH), Japanese language documentation, a unique consultation system, and adherence to specific Quality Management System (QMS) standards. While traditionally complex, the PMDA has modernized the process by introducing expedited pathways (such as SAKIGAKE) and accepting real-world data to address potential clinical trial gaps.

Vorpal guides you through Japan's complex regulatory and market access pathway across all stages of entry and commercialization. Whether you need full-scope support or phase-specific expertise, we deliver tailored solutions with confidence.

Contact us

Steps Toward Regulatory Approval

Initial Assessment & Strategy Development
We analyze your global data, identify regulatory gaps, and build a targeted PMDA submission strategy. Vorpal prepares high-quality, compliant documentation upfront to align with Japanese expectations and prevent submission delays.

Initial Assessment & Strategy Development

PMDA Consultation — Formatted Dialogue
PMDA consultations clarify regulatory expectations and optimize development strategies. Early feedback saves time and costs while building trust with reviewers. Vorpal guides you through the process to clear potential hurdles before filing.

PMDA Consultation — Formatted Dialogue

PMDA Review and Q&A
During PMDA evaluation, reviewers assess safety, efficacy, and quality standards (GCP, GLP, QMS). Vorpal coordinates prompt, consistent Q&A responses and prepares your team for inspections to navigate review smoothly.

PMDA Review and Q&A

Approval & Market Authorization
Securing approval is just the first step. Vorpal guides final-stage compliance, post-market planning, and the transition into Japan’s national reimbursement and pricing listing process for immediate commercial readiness.

Approval & Market Authorization

Focused man reviewing his colleagues screen during work session

REGULATORY & CLINICAL SUPPORT

Regulatory Strategy

A clear regulatory strategy is essential for navigating Japan's market entry. Device classification and pathway selection (Approval, Certification, or Notification) dictate timelines and costs. Vorpal aligns global data packages with PMDA expectations to define efficient pathways. We integrate regulatory requirements into early business planning and manage post-approval lifecycle changes to ensure ongoing compliance.

REGULATORY & CLINICAL SUPPORT

PMDA Consultations

PMDA consultations align clinical plans, data requirements, and submission strategies with reviewer expectations before filing. Vorpal structures discussions to reduce regulatory risks and avoid project delays. We also handle post-approval consultations—including lifecycle expansions and product changes—to maintain alignment with authorities and clear a smooth path forward.
Female doctor looking at report

REGULATORY & CLINICAL SUPPORT

Clinical Development

Japanese clinical evidence requirements depend on device risk, novelty, and equivalence. While global data is often leveraged, local trials may be required.

  • Clinical Development Planning — Evaluate global data, identify gaps, and align with PMDA expectations. Vorpal and IQVIA MedTech handle local Japanese trial planning and execution when needed.
  • Post-Approval Activities — Manage post-marketing surveillance (PMS) end-to-end. We leverage clinical evidence to support post-approval changes, indication expansions, and lifecycle updates.
Leveraging extensive industry experience and strong multilingual capabilities, our experts facilitate effective communication between clients and the PDMA throughout every phase of the regulatory journey.
Hiroshi Ichinose
Director, Regulatory Affairs

DMAH In-Country Representation

DMAH Services: Local regulatory representation and compliance support

If you choose the approval path with Designated Marketing Authorization Holder (DMAH), Vorpal should be your partner.

We provide comprehensive DMAH services covering PMV, quality, operation, and regulatory activities — ensuring seamless execution across product operations, domestic manufacturing coordination, and post‑market compliance, while enabling manufacturers to maintain confidence in regulatory integrity while focusing on their core business.

Contact us

DMAH IN-COUNTRY REPRESENTATION

Vorpal's DMAH Services

Success in Japan extends beyond regulatory approval — it requires end-to-end management of quality, operations, and compliance. Vorpal acts as your Designated Marketing Authorization Holder (DMAH), providing multidisciplinary support across PMDA interactions, quality systems, manufacturing coordination, and post-market obligations to scale your commercial presence with confidence.

Our proven results

16

ONGOING DMAH PROGRAMS

50+

LIFETIME DMAH PROGRAMS

20+

SUCCESSFUL DMAH TRANSFERS

Beyond supporting market entry as a DMAH, we help clients maintain compliance throughout the product lifecycle in Japan. Our flexible support spans PMV, QMS, Package Insert maintenance, and in-country logistics coordination, tailored to each client's needs. Whether full-service or targeted support is required, we adapt to their organization and resources.
Mayumi Takeuchi
Senior Director, Head or DMAH Operations, Safety Officer

Reimbursement & Market Access

Reimbursement & Market Access: Turning clinical and economic value into commercial success

Regulatory approval alone does not guarantee market adoption or optimal pricing. Vorpal bridges commercial, clinical, and regulatory disciplines to build evidence-backed reimbursement strategies. We handle MHLW interactions, pricing application preparation, and KOL engagement to demonstrate your product's value and secure long-term commercial success in Japan.
Contact us

DMAH IN-COUNTRY REPRESENTATION

Navigating Japan's Reimbursement Pathway

Helping manufacturers navigate Japan's reimbursement landscape from early strategy through stakeholder engagement and pricing approval.

Our proven results

20+

REIMBURSEMENT PROJECTS SINCE INCEPTION

10

NEW CATEGORY LISTINGS

6

NEW CATEGORY LISTINGS FOR LAST THREE YEARS

At Vorpal, we combine local market insight with global MedTech experience to help clients navigate Japan's complex reimbursement environment. Our goal is not to achieve favourable outcomes, but also to create a sustainable foundation for long-term commercial success.
Associate Director, Head of Market Access
Madoka Makishima

REGULATORY & CLINICAL SUPPORT

Broad Therapeutic Coverage

We support a wide range of medical technologies across diverse therapeutic areas, from SaMD to high-risk Class III/IV devices. Our team brings the expertise required to navigate varying regulatory expectations and development pathways, ensuring effective support regardless of device type or complexity.

Our proven results

250+

COMPANIES SUPPORTED

65

REGULATORY APPROVALS SECURED

50+

LIFETIME DMAH PROGRAMS

What differentiates us is our ability to connect global innovation with the realities of the Japanese healthcare environment. Clients rely on us for our deep insight into PMDA requirements, proven Shonin approval track record, and expertise in regulatory affairs and market access. Through close collaboration among our specialists and global stakeholders, we help clients achieve efficient approvals and commercial success in Japan.
We work with a diverse range of medical device companies, from global manufacturers entering Japan to organizations expanding their market presence. Clients often turn to us when facing regulatory or resource-related challenges, managing existing approvals, or pursuing opportunities in new therapeutic areas. Our role is to help them achieve their goals in Japan with confidence and efficiency.
Hitoshi Torii
General Manager
Yumi Yamamoto
Director, Project Management
Partner with experts who understand the path to adoption
From pricing strategy and stakeholder engagement to reimbursement support, Vorpal provides the insight and execution needed to help innovative technologies reach patients and healthcare providers throughout Japan.
CONTACT US

Frequently asked questions about Japan medical device registration process & Designated Marketing Authorization Holder (DMAH)

Medical devices in Japan must follow Pharmaceuticals and Medical Device Agency (PMDA) approval process under the PMD Act, including approval (Shonin), certification by notified body, or notification depending on classification of the device. Approval is required for higher-risk and novel devices.
To market a medical device in Japan, manufacturers must obtain regulatory approval and operate through a local Marketing Authorization Holder (MAH) or Designated Marketing Authorization Holder (DMAH).
The MAH is the domestic entity that holds the marketing approval, certification, or notification for the product. In contrast, the DMAH is the domestic entity appointed by the foreign manufacturer (Foreign Special Approval Holder) to carry out domestic responsibilities in Japan on its behalf.
Yes, however, a planned and well-controlled transition is required. When changing the DMAH, activities such as the transfer of regulatory documentation, handover of QMS and GVP systems, transfer of product technical documentation and labeling (including package inserts), as well as notifications and filings with the regulatory authorities will be necessary.
Yes, companies can outsource specific functions such as regulatory file development based on their needs. Please contact us for further details.
PMDA consultations provide regulatory guidance on clinical development, data requirements, and submission strategies, helping align development with regulatory expectations.
Clinical data requirements depend on device novelty and equivalence. Some devices can leverage existing data from foreign studies, while others require local clinical trials. We can help to develop the strategy to meet your goal.
Reimbursement in Japan is determined under the National Health Insurance (NHI) system, where the government establishes pricing and coverage.
The reimbursement pathway depends on whether the device can be covered under an existing category or requires a new evaluation. Certain new medical devices may require MHLW and Chuikyo review for reimbursement and pricing.
Yes, definitely. Regulatory interactions with PMDA and MHLW are conducted in Japanese and require local expertise and experience.

Subscribe to IQVIA MedTech Perspectives

Receive our latest thinking on various key issues shaping the MedTech industry.
Subscribe

Relates solutions

Contact Us